Rodin raises $27M series B

Rodin Therapeutics Inc. (Cambridge, Mass.) raised $27 million in a tranched series B round from existing investor Atlas Venture and new investors GV, Hatteras Venture Partners, Remeditex Ventures and Third Point Ventures. Details regarding the tranches are not disclosed.

Rodin is developing selective HDAC2 inhibitors to treat neurological disorders. The company plans to select a lead candidate this year and bring it into the clinic in 2018 to treat cognitive impairment in Alzheimer's disease (see BioCentury Innovations, April 14, 2016). ...